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NaftopidilAbstract A highly sensitive and simple high-performance liquid chromatographic–tandem mass
spectrometric (LC–MS-MS) assay is developed and validated for the quantiﬁcation of Naftopidil
in human plasma. Naftopidil is extracted from human plasma by methyl tertiary butyl ether and
analyzed using a reversed-phase gradient elution on a discovery C 18 5 l (50 · 4.6) column. A meth-
anol: 2 mM ammonium formate (90:10) as mobile phase, is used and detection was performed by
MS using electrospray ionization in positive mode. Propranolol is used as the internal standard.
The lower limits of quantiﬁcation are 0.495 ng/mL. The calibration curves are linear over the con-
centration range of 0.495–200.577 ng/mL of plasma for each analyte. This novel LC–MS-MS
method shows satisfactory accuracy and precision and is sufﬁciently sensitive for the performance
of pharmacokinetic studies in humans.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
Naftopidil, a phenylpiperazine derivative, is a novel alpha1-
adrenoceptor antagonist and is a new drug for the bladder out-
let obstruction in patients with benign prostatic hyperplasia
(BPH). Naftopidil is chemically 1-[4-(2-methoxyphenyl)pipera-
zin-1-yl]-3-(1-naphthyloxy)propan-2-ol (Fig. 1) used to treat
‘hypertension’, Naftopidil exerts its antihypertensive action
via alpha1-adrenoceptor blockage and Ca2+ antagonism in
vascular smooth muscle (Kirsten et al., 1994). Naftopidil com-
petitively inhibited speciﬁc [3H] prazosin binding in prostatic
membranes of humans. Naftopidil was selective for the alpha
1d-adrenoceptor with approximately 3- and 17-fold higher
Figure 2 Structure of propranolol.
Figure 1 Structure of Naftopidil.
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types, respectively. In addition to the antagonistic action of
this agent on the alpha1 adrenergic receptors of prostatic
smooth muscle naftopidil may also act on the lumbosacral
cord and thus may improve collecting disorders in patients
with benign prostatic hyperplasia (Sugaya et al., 2002). In this
way they reduce the pressure on the urethra and so help in-
crease the ﬂow of urine. Newly developed alpha1 adrenoceptor
antagonists including naftopidil are free from the ‘‘prazosin-
like’’ side effect of orthostatic hypotension and associated
symptoms (Take et al., 1998). Naftopidil a novel antihyperten-
sive compound, possesses 5HT1 antagonistic properties in
addition to being an alpha1 adrenoceptor antagonist (Borbe
et al., 1991).
Several chromatographic methods including liquid chroma-
tography–UV (LC–UV) (Jinsong et al., 2000; Kirsten et al.,
1994; Li et al., 2006; Sugaya et al., 2002), LC – isotope dilution
mass spectrometry (Agostini et al., 1989), and HPLC mass
spectrometry (LCMS) (Li et al., 2006) have been developed
to measure naftopidil in biological ﬂuids. All these reported
methods are inadequate because of insufﬁcient sensitivity,
along chromatographic runtime, more plasma volume requiredFigure 3 Full scan and produfor sample processing, and a high injection volume, but still no
LC–MS/MS method has been developed and validated in hu-
man plasma. (See Figs. 2 and 3).
2. Experimental
2.1. Reagents and chemicals and samples
Pharmaceutical grade naftopidil was supplied by Erregierre
Pharmaceuticals (Italy) and was certiﬁed to contain 99.8%
Naftopidil. Propranolol was supplied by Cadila healthcare
limited and was certiﬁed to contain 96.9% Propranolol. Both
standards were used without further puriﬁcation. The organic
solvents used were of gradient grade and were obtained from
Spectrochem. Water was obtained from a Milli-Q Gradient
water puriﬁcation system (Millipore, Barnstead). Ammonium
formate, used for mobile phase preparation, was of GR grade
and obtained from Merck.
2.2. Chromatographic conditions
A shimadzu UFLC2695LC instrument was used in this study.
Separation was carried out on a Discovery C18 column
(50 mm_4.6 mm, 5 l) maintained at 40 C. The LC mobile
phase consisted of methanol: ammonium formate (90:10, v/
v). The ﬂow rate was 0.5 mL/min. The injection volume was
10 lL, and the runtime was 3.0 min.
2.3. Mass spectrometry conditions
Detection was carried out by a Applied Biosystem MDS Sciex
API 4000 triple-quadrupole MS ﬁtted with an electrospray
ionization (ESI) probe and operated in the positive ion mode.
The following parameters were optimal: capillary voltage,
5500 V; ion source temperature, 400 C; GS1, 45; GS2, 55.
Detection was carried out in multiple reaction monitoring
(MRM) mode. Nitrogen was used as the collision gas. Other
parameters are shown in Table 1. Mass spectra of IS (Propra-
nalol) were taken from the literature (Upthagrove et al., 1999).ct ion spectra of naftopidil.
Table 1 Mass spectrometer parameters.
Parameters Value
Source temperature (C) 400
Dwell time per transition (ms) 200
Ion source gas (gas 1) (psi) 45
Ion source gas (gas 2) (psi) 55
Curtain gas (psi) 30
Collision gas (psi) 5
Ion spray voltage (V) 5500
Entrance potential (V) 12 (analyte) and 10 (IS)
Declustering potential (V) 85 (analyte) and 40 (IS)
Collision energy (V) 39 (analyte) and 25 (IS)
Collision cell exit potential (V) 14 (analyte) and 7 (IS)
Mode of analysis Positive
Ion transition for naftopidil (m/z) 393.5/205.4
Ion transition for propranolol (m/z) 260.3/116.2
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Standard stock solutions of naftopidil (1 mg/mL) and the IS
(1 mg/mL) were separately prepared in 10 mL volumetric
ﬂasks with methanol. Working solutions for calibration and
controls were prepared from the stock solution by adequate
dilution using diluent (methanol: water, 50:50, v/v). The IS
working solution (250 ng/mL) was prepared by diluting its
stock solution with diluent. Working solutions (20 lL) were
added to 980 lL drug-free human plasma to obtain naftopidil
concentration levels of 0.495, 0.990, 10.999, 32.350, 111.553,
141.206, 176.508, and 200.577 ng/mL. Quality control (QC)
samples were prepared as a bulk based on an independent
weighing of standard drug, at concentrations of 0.512 ng/mL
(LLOQ), 1.384 ng/mL (low), 98.884 ng/mL (medium) and
170.490 ng/mL (high) as a single batch at each concentration.
These samples were divided into aliquots in microcentrifuge
tubes (Tarson, 0.3 mL) and stored in the freezer at below
50 C until analysis.
2.5. Sample preparation
Sample preparation involved a liquid–liquid extraction with
Methyl tertiary buty ether. Spiked plasma stability samples
of naftopidil were removed from the deep freezer and main-
tained below 70 C and left at room temperature to thaw.
The samples were vortexed, mixed adequately, and centrifuged
before pipetting. As soon as the stability samples were thawed,
these samples were aliquoted (0.2 ml) and freshly prepared. CS
and QC samples were spiked with 50 lL IS (250.0 ng/mL) into
pre labeled RIA vials to each tube except blank and mixed for
30 s on vortexer. To this 50 lL 5% ammonia was added toTable 2 Intra batch accuracy and precision.
Quality control samples Concentration added (ng/mL) Concentration
LLOQ QC 0.512 0.567 ± 0.0
LQC 1.384 1.586 ± 0.1
MQC 98.884 100.490 ± 2.1
HQC 170.490 169.979 ± 5.3each tube and vortexed for 30 s. 2 ml extraction of solvent
methyl tertiary butyl ether was added to each tube and vor-
texed for 3 min. Samples were centrifuged at 4600 RPM for
5 min at 10 C. Supernatant layer was separated and evapo-
rated in nitrogen gas up to dryness, reconstituted with
300 lL reconstitution solution (Methanol: 2 mM Ammonium
formate (pH-7.00 (90:10) and vortexed for 1 min. The samples
were transferred to HPLC vials for analysis.
3. Method validation
3.1. Speciﬁcity
To verify the absence of interfering substances around the
retention time of analytes, 20 blank samples were analyzed.
3.2. Linearity
Calibration curves were constructed using matrix-matched
standard solutions by plotting the peak area of the quantitative
ion of each analyte versus concentrations. Concentration range
was found to be 5–150 lg/mL and correlation coefﬁcient was
0.999.
3.3. Limit of detection and quantitation
The limits of detection (LODs), deﬁned as the lowest concen-
tration that the analytical process can reliably differentiate
from background levels, were estimated for those concentra-
tions that provide a signal-to-noise ratio of 3:1 which was
found to be 0.19. The LOQs were estimated at a signal-to-noise
ratio of 10:1 found to be 0.57.
3.4. Accuracy and precision
Intra-assay precision and accuracy were calculated at LLOQ
(0.512 ng/mL), low quality-control (LQC, 1.384 ng/mL), mid-
dle quality-control (MQC, 98.884 ng/mL), and high quality-
control (HQC, 170.490 ng/mL) levels for the six replicates,
each of the same analytical run. Inter-assay precision and
accuracy were calculated after the replicates in six different
analytical runs. (Tables 2 and 3).
3.5. Recovery
The recovery of naftopidil was calculated by comparing the
peak area of the analyte from the extracted plasma standard
with that obtained from an un-extracted standard at the same
concentration for the QC samples containing, 1.384, 98.884,
170.490 ng/mL. IS recovery was tested at 500.0 ng/mL byfound (ng/mL) (mean ± S.D.) Precision (%) CV Accuracy (%)
6 10.5 110.7
8 11.4 114.6
5 2.1 101.6
3 3.1 99.7
Table 3 Inter batch precision and accuracy.
Quality control
samples
Concentration added
(ng/mL)
Concentration found (ng/mL)
(mean ± S.D.) (n= 3)
Precision (%)
CV
Accuracy
(%)
LLOQ 0.512 0.476 ± 0.08 16.3 93.0
LQC 1.384 1.479 ± 0.13 8.8 106.9
MQC 98.884 101.866 ± 4.72 4.6 103.0
HQC 170.490 173.095 ± 8.23 4.8 101.5
n=No. of estimation.
Table 4 Stability data of Naftopidil.
Stability
experiments
Recovery (%) Sample concentration (ng/
mL) (n= 6) LQC, HQC
Concentration found
(ng/mL) (mean ± S.D.)
% Mean change at
quality control level
Three freeze–
thaw cycles
After 3rd FT cycle
at (20 ± 5 C)
1.384 1.475 ± 0.0345 6.6
170.490 177.679 ± 3.9514 4.2
Autosampler
stability for
47 h at 6 C 1.384 1.383 ± 0.0617 0.0
170.490 165.218 ± 5.0777 3.1
Bench top
stability for
At room
temperature (20 h)
1.384 1.480 ± 0.0253 6.9
170.490 176.820 ± 2.6191 3.7
Dry extract
stability
At 70 C 1.384 1.357 ± 0.0870 2.0
170.490 166.820 ± 4.6241 2.2
n=No. of estimation.
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centration. (Table 4).
3.6. Matrix effect
The matrix effects were investigated for six different samples of
plasma, comprising four lots of normal control heparinized
plasma, one lot of lipemic plasma, and one lot of hemolyzed
plasma. Three samples each at the LQC and HQC levels were
prepared from different lots of plasma (i.e., a total of 36 QC
samples) and checked for accuracy to see whether the matrix
affected the back-calculated value of the nominal concentra-
tions for these different plasma samples. The back-calculated
concentrations of all LQC and HQC samples must be within
85–115% of their nominal concentration. At least 67% of
QC samples must fall within the above-mentioned criteria at
each LQC and HQC levels.
4. Stability
Exhaustive experiments were performed to assess the stability
of naftopidil in stock solution and in plasma samples under dif-
ferent conditions, simulating the conditions occurring during
the analysis of study samples: room-temperature stability, ex-
tracted sample stability (process stability), freeze–thaw stabil-
ity, and the long-term stability of plasma samples, dry
extract stability, and stock solution stability.
5. Results and discussion
5.1. Method development and optimization
The chromatographic conditions, especially the composition
of mobile phase, were optimized through several trials toachieve good resolution and symmetric peak shapes for the
analyte and the IS, as well as short run time. Modiﬁers such
as ammonia and ammonium formate alone or in combination
in different concentrations were added. It was found that a
mixture of Methanol: 2 mM ammonium formate (90:10, v/v;
pH 7.0) could achieve this purpose and was ﬁnally adopted
as the mobile phase. Ammonia was found to be necessary in
order to lower the pH to protonate naftopidil and thus deliver
a good peak shape. The percentage of ammonia was optimized
to maintain this peak shape while being consistent with good
ionization and fragmentation in the mass spectrometer.
The tandem mass spectrometer allows the selective detec-
tion of substances with varying masses or fragments without
chromatographic separation. The development of the chro-
matographic system was focused on short retention times in
order to assure high throughput, paying attention to matrix ef-
fects as well as good peak shapes. The high proportion of or-
ganic solvent (Methanol: 2 mM ammonium formate (90:10, v/
v; pH 7.0)) eluted the analyte and the IS at retention times of
1.8 and 1.6 min, respectively. A ﬂow-rate of 0.500 mL/min
produced good peak shapes and permitted a run-time to 3 min.
Internal standard is necessary for the determination of ana-
lyte in biological samples. In the initial stages of this work, sev-
eral compounds were investigated to ﬁnd a suitable internal
standard and ﬁnally Propranolol, structurally related to naf-
topidil, was found to be the best for the present purpose.
Clean chromatograms were obtained and no signiﬁcant di-
rect interferences in the MRM channels at the relevant reten-
tion times were observed. However, in ESI, signal
suppression or enhancement may occur due to co-eluting
endogenous components of the sample matrix. These potential
matrix effects were evaluated by spiking blank plasma extracts
at the low and high QC levels. The resulting chromatograms
were compared with those obtained for clean standard solu-
tions at the same concentrations. Three independent plasma
Figure 4 Typical representative chromatograms (a) chromatogram of blank plasma, (b) chromatogram of blank + IS, (c) chromtogram
of LLOQ.
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(data not shown) showed that there was no signiﬁcant differ-
ence between peak responses for spiked plasma extracts and
clean solutions.
5.2. Method validation
The developed method was validated in terms of speciﬁcity,
linearity, precision and accuracy, recovery, matrix effect, sta-
bility, dilution integrity (Yu et al., 1995).
5.2.1. Speciﬁcity
The speciﬁcity of the method was investigated by comparing
chromatograms obtained from six different sources of plasma.
The area observed at the retention time of naftopidil was much
less than 20% of the LLOQ area (0.512 ng/mL). The represen-
tative chromatograms, shown in Fig. 4a and b, indicate that
there was no interference with the analyte and IS from endog-
enous substances in the plasma.
5.2.2. Linearity
The linearity of the method was determined by a weighted
least-square linear regression analysis of standard plots associ-
ated with eight-point standard calibration curves. Best-ﬁt cal-
ibration curves of peak-area ratio against the concentration
were drawn. The concentration of naftopidil was calculated
from the simple linear equation using a regression analysis of
the spiked plasma CSs with a reciprocal of the square of the
drug concentration, 1/x2, as a weighting factor. The calibration
plots were linear from 0.495–200.577 ng/mL with r2 0.9984.
(Fig. 5).
5.2.3. Precision and accuracy
The within batch % coefﬁcient of variation for naftopidil was
ranged from 2.0% to 11.4% and % accuracy was ranged fromFigure 5 Linearity81.9% to 114.6%. The results are within ±15%. (Tables 2 and
3).
5.2.4. Recovery
The percent mean recovery for naftopidil was observed as
81.91. The mean recovery of IS was 74.4% at a concentration
500.0 ng/mL.
5.2.5. Matrix effect
Processed and analyzed calibration standards in the same ma-
trix which is to be used during validation experiment and three
replicates from three different lots of plasma at LQC and HQC
levels as per the procedure are described in the sample prepa-
ration section. % Nominal concentration was found to be
104% (LQC) and 100.5% (HQC) for the dilutions, which
passed the limit of 85–115%.
5.2.6. Dilution integrity
Analyte spiking stock solution was spiked in blank plasma to
get concentration equivalent to three times of ULOQ and di-
luted with blank plasma to get 1/5 and 1/10 concentrations
of the spiked sample or as per requirement. Calibration stan-
dards and six aliquots each of diluted samples (1/5 and 1/10
dilutions) were processed and analyzed as per the procedure
as described in sample preparation. Precision and accuracy
of the dilution integrity of the QC’s should be 615% and with-
in ±15% of the nominal concentration, respectively. % Nom-
inal concentration was found to be 109.6% (1/5 concentration)
and 108.9% (1/10 concentration) for the dilutions, which
passed the limit of 85–115%.
5.2.7. Solution stability
The stability of the analyte and IS in human plasma under dif-
ferent temperature and timing conditions, as well as the stabil-
ity in stock solution, was evaluated as follows. All the stabilityof Naftopidil.
654 P.S. Jain et al.studies were carried out at two concentration levels (1.384 and
170.490 ng/mL as low and high values) with six determinations
for each.
For short-term stability determination, stored plasma ali-
quots were thawed and kept at room temperature for a period
of time exceeding that was expected to be encountered during
the routine sample preparation (around 6 h). These results
indicate reliable stability behavior under the experimental con-
ditions of the regular analytical procedure.
The stability of QC samples kept in the autosampler for
25 h was also assessed. The results indicate that solutions of
naftopidil and IS can remain in the autosampler for at least
25 h, without showing a signiﬁcant loss in the quantiﬁed val-
ues, indicating that samples should be processed within this
period of time Table 4.
The data representing the stability of naftopidil in plasma
at two QC levels over three freeze and thaw cycles are given
in Table 3. These tests indicate that the analyte is stable in hu-
man plasma for three freeze and thaw cycles, when stored at
below 20 C and thawed to room temperature.
The stability study of naftopidil in human plasma showed
reliable stability behavior, as the mean of the results of the
tested samples was within the acceptance criteria of ±15%
of the initial values of the controls. These ﬁndings indicate that
storage of naftopidil in plasma samples at below 20 C is
adequate, and no stability-related problems would be expected
during routine analysis for pharmacokinetic, bioavailability or
bioequivalence studies.
The stability of stock solutions was tested and established
at room temperature for 6 h and under refrigeration (2–8 C)
for 8 days. The recoveries for naftopidil and IS were 77.3%
(low Q.C), 69.2% (middle Q.C), 59.5% (higher Q.C) and
74.4% respectively. The results revealed optimum stability
for the prepared stock solutions throughout the period in-
tended for their daily use.
6. Conclusion
In summary, the LC–MS/MS method for the quantitation of
naftopidil in human plasma was developed and fully validated
as per FDA guidelines. This method offers signiﬁcant advanta-
ges over those previously reported, in terms of improved sen-
sitivity and selectivity, faster run time (3 min) and lower
sample requirements. Thus the volume of samples to be col-
lected per time point from an individual during trial is reduced
signiﬁcantly, allowing inclusion of additional points. Withdilution integrity up to 10-fold, we have established that the
upper limit of quantiﬁcation is extendable up to 200.577 ng/
mL. Hence, this method is useful for single and multiple
ascending dose studies in human subjects. The current method
has shown acceptable precision and adequate sensitivity for the
quantiﬁcation of naftopidil in human plasma samples obtained
for pharmacokinetic, bioavailability or bioequivalence studies.
The desired sensitivity of naftopidil was achieved with an
LLOQ of 0.495 ng/mL, which has a within and between-batch
CV of 10.5 and 16.3%, respectively. The sensitivity could be
further improved by sample concentration. The simplicity, li-
quid–liquid extraction and sample turnover rate of 2 min per
sample, make it an attractive procedure in high-throughput
bioanalysis of naftopidil. The validated method allows quanti-
ﬁcation of naftopidil in the 0.495–200.577 ng/mL range.Acknowledgments
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